Foghorn Therapeutics Inc. Stock Price, News & Analysis

Foghorn Therapeutics (Nasdaq: FHTX) has announced its participation in two virtual investor conferences. The first is the Morgan Stanley Virtual Annual Global Healthcare Conference on September 9, 2021, featuring a fireside chat and one-on-one meetings. The second is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, with a presentation and one-on-one meetings. Presentations will be available on-demand, and replays can be accessed for 90 days. Foghorn focuses on developing medicines that target the chromatin regulatory system in oncology.

Foghorn Therapeutics has announced the initiation of a first-in-human clinical trial for FHD-609, a selective protein degrader targeting BRD9, aimed at treating advanced synovial sarcoma. The trial marks a significant milestone for Foghorn's Gene Traffic Control platform, which focuses on addressing substantial unmet medical needs in oncology. FHD-609 seeks to exploit a synthetic lethal relationship with specific genetic mutations in synovial sarcoma. The company anticipates initial clinical data to be available in early 2022.

Foghorn Therapeutics has made significant advancements in its clinical programs, announcing the first patients dosed in Phase 1 trials of FHD-286 targeting metastatic uveal melanoma and relapsed acute myeloid leukemia. Additionally, they received IND clearance for FHD-609, a protein degrader for synovial sarcoma. The company's cash position as of June 30, 2021, stood at $141.3 million, down from $185.8 million at year-end 2020. Upcoming milestones include initial data for FHD-286 expected in Q4 2021 and for FHD-609 anticipated in H1 2022.

Foghorn Therapeutics (Nasdaq: FHTX) announced that Steven Bellon, Ph.D., Senior Vice President of Drug Discovery, will speak at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021, at 10:20 a.m. ET. The panel titled 'Bullseye – Targeted Oncology Part 2' will discuss advancements in oncology. Additionally, Foghorn's management will conduct investor meetings during the event. A live webcast of the panel can be accessed in the Investors section of their website, www.foghorntx.com.

Foghorn Therapeutics (Nasdaq: FHTX) announces participation in the William Blair Biotech Focus Conference 2021 with CEO Adrian Gottschalk on July 15 at 9:00 a.m. ET. The conference will focus on next-generation small molecules in oncology. A live webcast of the panel can be accessed through the company’s website under the ‘Events & Presentations’ section. Foghorn is dedicated to developing a novel class of medicines targeting genetically determined dependencies in the chromatin regulatory system, with ongoing projects in oncology.

Foghorn Therapeutics Inc. (Nasdaq: FHTX) will host a research and development webinar on June 15, 2021, from 9:00 AM to 11:00 AM EDT. Key presentations will be made by management and experts from notable institutions, including Howard A. Burris III and Eytan Stein. The event will cover the significance of the chromatin regulatory system in gene expression and its application in precision oncology, featuring Foghorn's Gene Traffic Control platform. A live Q&A session will follow the presentations. Registration is available online.

Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced that CEO Adrian Gottschalk will present at two upcoming investor conferences. The Jefferies Virtual Healthcare Conference is scheduled for June 1, 2021, at 10:00 am ET, featuring a presentation and one-on-one meetings. The Goldman Sachs 42nd Annual Healthcare Conference will take place on June 8, 2021, at 8:00 am ET, including a fireside chat and one-on-one meetings. Interested investors can access the live webcasts through the company’s website under the “Events & Presentations” section.

Foghorn Therapeutics (Nasdaq: FHTX) announced the first patient has been dosed in a first-in-human clinical trial of FHD-286, targeting metastatic uveal melanoma (mUM) and relapsed/refractory acute myelogenous leukemia (AML). This marks a significant milestone as FHD-286 is the first clinical candidate from Foghorn's diverse pipeline, designed to inhibit the chromatin regulatory system. Both trials are open-label and focus on safety and efficacy, highlighting Foghorn's innovative approach to treating cancers with limited options.

Foghorn Therapeutics (Nasdaq: FHTX) received IND clearance for FHD-609, a targeted protein degrader for synovial sarcoma. This marks a significant milestone alongside advancement in their therapeutic pipeline aimed at the chromatin regulatory system. FHD-609 is Foghorn's second drug to enter clinical trials, with initial data expected in early 2022. The company also received IND clearance for FHD-286, targeting relapsed AML and metastatic uveal melanoma. Financially, Foghorn reported cash and equivalents of $160.9 million as of March 31, 2021, down from $185.8 million at year-end 2020.